Related Experiment Video
Updated: Jun 21, 2026
07:52
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
[Ongoing medical problems in the anti-doping fight].
Charles Delagardelle1, Fernand Ries, Patrick Feiereisen
1Service de cardiologie, Centre Hospitalier, Luxembourg.
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg
|December 19, 2007
Summary
Systematic doping, including Erythropoietin (EPO) and anabolic steroids (AAS), threatens elite sports. Improved detection methods exist, but growth hormone (GH) detection remains a challenge for anti-doping efforts.
Area of Science:
- Sports Science
- Anti-Doping Research
- Pharmacology
Context:
- Systematic doping poses a significant threat to elite sports integrity.
- Doping practices have evolved with new performance-enhancing substances.
- The anti-doping control system influences current doping methodologies.
Purpose:
- To review current doping agents and their impact on elite sports.
- To assess the effectiveness and limitations of anti-doping control systems.
- To highlight future challenges in combating doping.
Summary:
- Major doping categories include anabolic steroids (AAS), Erythropoietin (EPO), and growth hormone (GH).
- EPO has revolutionized endurance sports, while GH detection remains a significant weakness in current controls.
- Novel, highly effective drugs are emerging, necessitating advanced detection strategies.
Impact:
- Enhanced detection methods for EPO and AAS have been developed.
- The inability to detect GH presents a major vulnerability in anti-doping.
- Future anti-doping efforts must focus on intelligent, quality-driven controls for the survival of elite sport.
Related Concept Videos
01:36Humoral Immune Responses
Overview
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...